These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 25858498)

  • 1. Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model.
    Chugh R; Griffith KA; Davis EJ; Thomas DG; Zavala JD; Metko G; Brockstein B; Undevia SD; Stadler WM; Schuetze SM
    Ann Oncol; 2015 Jul; 26(7):1459-64. PubMed ID: 25858498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial.
    Schwartz GK; Tap WD; Qin LX; Livingston MB; Undevia SD; Chmielowski B; Agulnik M; Schuetze SM; Reed DR; Okuno SH; Ludwig JA; Keedy V; Rietschel P; Kraft AS; Adkins D; Van Tine BA; Brockstein B; Yim V; Bitas C; Abdullah A; Antonescu CR; Condy M; Dickson MA; Vasudeva SD; Ho AL; Doyle LA; Chen HX; Maki RG
    Lancet Oncol; 2013 Apr; 14(4):371-82. PubMed ID: 23477833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer.
    Ma CX; Suman VJ; Goetz M; Haluska P; Moynihan T; Nanda R; Olopade O; Pluard T; Guo Z; Chen HX; Erlichman C; Ellis MJ; Fleming GF
    Breast Cancer Res Treat; 2013 May; 139(1):145-53. PubMed ID: 23605083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I/II study of erlotinib in combination with the anti-insulin-like growth factor-1 receptor monoclonal antibody IMC-A12 (cixutumumab) in patients with advanced non-small cell lung cancer.
    Weickhardt A; Doebele R; Oton A; Lettieri J; Maxson D; Reynolds M; Brown A; Jackson MK; Dy G; Adjei A; Fetterly G; Lu X; Franklin W; Varella-Garcia M; Hirsch FR; Wynes MW; Youssoufian H; Adjei A; Camidge DR
    J Thorac Oncol; 2012 Feb; 7(2):419-26. PubMed ID: 22237261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors.
    Naing A; LoRusso P; Fu S; Hong DS; Anderson P; Benjamin RS; Ludwig J; Chen HX; Doyle LA; Kurzrock R
    Clin Cancer Res; 2012 May; 18(9):2625-31. PubMed ID: 22465830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: a report from the Children's Oncology Group.
    Wagner LM; Fouladi M; Ahmed A; Krailo MD; Weigel B; DuBois SG; Doyle LA; Chen H; Blaney SM
    Pediatr Blood Cancer; 2015 Mar; 62(3):440-4. PubMed ID: 25446280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial.
    Tap WD; Jones RL; Van Tine BA; Chmielowski B; Elias AD; Adkins D; Agulnik M; Cooney MM; Livingston MB; Pennock G; Hameed MR; Shah GD; Qin A; Shahir A; Cronier DM; Ilaria R; Conti I; Cosaert J; Schwartz GK
    Lancet; 2016 Jul; 388(10043):488-97. PubMed ID: 27291997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I trial of escalating doses of cixutumumab (IMC-A12) and sorafenib in the treatment of advanced hepatocellular carcinoma.
    El-Khoueiry AB; O'Donnell R; Semrad TJ; Mack P; Blanchard S; Bahary N; Jiang Y; Yen Y; Wright J; Chen H; Lenz HJ; Gandara DR
    Cancer Chemother Pharmacol; 2018 May; 81(5):957-963. PubMed ID: 29520435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas.
    Asmane I; Watkin E; Alberti L; Duc A; Marec-Berard P; Ray-Coquard I; Cassier P; Decouvelaere AV; Ranchère D; Kurtz JE; Bergerat JP; Blay JY
    Eur J Cancer; 2012 Nov; 48(16):3027-35. PubMed ID: 22682017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas: The ANNOUNCE Randomized Clinical Trial.
    Tap WD; Wagner AJ; Schöffski P; Martin-Broto J; Krarup-Hansen A; Ganjoo KN; Yen CC; Abdul Razak AR; Spira A; Kawai A; Le Cesne A; Van Tine BA; Naito Y; Park SH; Fedenko A; Pápai Z; Soldatenkova V; Shahir A; Mo G; Wright J; Jones RL;
    JAMA; 2020 Apr; 323(13):1266-1276. PubMed ID: 32259228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours.
    Wilky BA; Rudek MA; Ahmed S; Laheru DA; Cosgrove D; Donehower RC; Nelkin B; Ball D; Doyle LA; Chen H; Ye X; Bigley G; Womack C; Azad NS
    Br J Cancer; 2015 Jan; 112(1):24-31. PubMed ID: 25268371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcoma.
    Blay JY; von Mehren M; Samuels BL; Fanucchi MP; Ray-Coquard I; Buckley B; Gilles L; Lebedinsky C; Elsayed YA; Le Cesne A
    Clin Cancer Res; 2008 Oct; 14(20):6656-62. PubMed ID: 18927308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors.
    Quek R; Wang Q; Morgan JA; Shapiro GI; Butrynski JE; Ramaiya N; Huftalen T; Jederlinic N; Manola J; Wagner AJ; Demetri GD; George S
    Clin Cancer Res; 2011 Feb; 17(4):871-9. PubMed ID: 21177764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Prevalence and Impact of Hyperglycemia and Hyperlipidemia in Patients With Advanced Cancer Receiving Combination Treatment With the Mammalian Target of Rapamycin Inhibitor Temsirolimus and Insulin Growth Factor-Receptor Antibody Cixutumumab.
    Busaidy NL; LoRusso P; Lawhorn K; Hess KR; Habra MA; Fu S; Hong DS; Chen HX; Doyle LA; Kurzrock R; Naing A
    Oncologist; 2015 Jul; 20(7):737-41. PubMed ID: 26054632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase I Trial of IGF-1R Inhibitor Cixutumumab and mTOR Inhibitor Temsirolimus in Metastatic Castration-resistant Prostate Cancer.
    McHugh DJ; Chudow J; DeNunzio M; Slovin SF; Danila DC; Morris MJ; Scher HI; Rathkopf DE
    Clin Genitourin Cancer; 2020 Jun; 18(3):171-178.e2. PubMed ID: 32057715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and Efficacy of the Combination Lurbinectedin plus Doxorubicin from a Phase 1b Trial in Patients with Advanced/Metastatic Soft-Tissue Sarcoma.
    Cote GM; Haddox CL; Choy E; Merriam PA; Mazzola E; Venkataraman V; Alcindor T; Wagner AJ; Demetri GD; George S
    Clin Cancer Res; 2024 Jul; 30(13):2702-2708. PubMed ID: 38723278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase 1b trial of selinexor, a first-in-class selective inhibitor of nuclear export (SINE), in combination with doxorubicin in patients with advanced soft tissue sarcomas (STS).
    Lewin J; Malone E; Al-Ezzi E; Fasih S; Pedersen P; Accardi S; Gupta A; Abdul Razak A
    Eur J Cancer; 2021 Feb; 144():360-367. PubMed ID: 33418486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and Translational Results of a Phase II, Randomized Trial of an Anti-IGF-1R (Cixutumumab) in Women with Breast Cancer That Progressed on Endocrine Therapy.
    Gradishar WJ; Yardley DA; Layman R; Sparano JA; Chuang E; Northfelt DW; Schwartz GN; Youssoufian H; Tang S; Novosiadly R; Forest A; Nguyen TS; Cosaert J; Grebennik D; Haluska P
    Clin Cancer Res; 2016 Jan; 22(2):301-9. PubMed ID: 26324738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I/II study of docetaxel, ifosfamide, and doxorubicin in advanced, recurrent, or metastatic soft tissue sarcoma (STS).
    Suppiah R; Wood L; Elson P; Budd GT
    Invest New Drugs; 2006 Nov; 24(6):509-14. PubMed ID: 16791410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 1 study of oral abexinostat, a histone deacetylase inhibitor, in combination with doxorubicin in patients with metastatic sarcoma.
    Choy E; Flamand Y; Balasubramanian S; Butrynski JE; Harmon DC; George S; Cote GM; Wagner AJ; Morgan JA; Sirisawad M; Mani C; Hornicek FJ; Duan Z; Demetri GD
    Cancer; 2015 Apr; 121(8):1223-30. PubMed ID: 25536954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.